CompanyELOXNasdaqArlington, MA

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals develops small-molecule ribosomal modulators that promote readthrough of premature stop codons from nonsense mutations.

SEC EDGAR ClinicalTrials.gov eloxxpharma.com

S-1Sep 11Latest SEC filing

Aug 11Latest story

August 2026

Eloxx reports Q2 2026 results after $66 million raise and Nasdaq uplisting

Aug 11Quarterly updateEloxx Pharmaceuticals, Inc.